ReviewHematology. American Society of Hematology. Education Program2025
Molecular approach to cytopenia and bone marrow failure.
Review in Hematology. American Society of Hematology. Education Program, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytopenias are common in the adult population, with increasing recognition of clonal hematopoiesis and inherited syndromes due to widespread molecular testing. Clonal hematopoiesis is a premalignant spectrum of disorders characterized by a somatic myeloid mutation, including clonal hematopoiesis of indeterminate potential and clonal cytopenia of uncertain significance. Inherited bone marrow failure syndromes (IBMFS) can also be found during workup of incidental cytopenias, even in the absence of other syndromic associations. In clonal cytopenia of uncertain significance, the overall risk of progressing to a myeloid neoplasm can be affected by the type of mutation, number of mutations, and variant allele frequency. Prognostication systems, such as the Clonal Hematopoiesis Risk Score, MN-predict, and Clonal Cytopenia Risk Score, can help determine the risk of malignant progression. Context-dependent factors like chemotherapy, radiation, and smoking can influence this risk. For suspected IBFMS, workup typically includes telomere length testing and chromosomal breakage analysis, along with comprehensive germline testing. If IBMFS is confirmed, further testing may be indicated based on the syndrome, as patients are often at risk of other organ dysfunction and malignancies. In these patients, stem cell transplantation may be indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.